FILTER
LATEST INTERVIEWS
Manuel Fumagalli
PRESIDENT, ORGANIZING COMMITTEE, 13TH INT. GOLD AND SILVER SYMPOSIUM
This year’s International Gold and Silver Symposium, taking place on 29th of May in Peru, will focus on technology and innovation.
Patrick Soares
FORAN MINING
Foran mining continue to expand the resource bace at its McIlvenna Bay property in preparation for an upturn.
Nick Grasman
LEAD MARKET MANAGER, DOW PHARMA SOLUTIONS, THE DOW CHEMICAL COMPANY
Dow Pharma Solutions develops functional excipients and APIs that enable improved pharmaceutical delivery and enhanced solubility.
Steve Dixon
CEO, STRACON
STRACON’s CEO, Steve Dixon, provides its vision and strategy as it enters a new phase under new owners.
Jay Dong
GENERAL MANAGER and GLOBAL VP, CST CHINA
CST is expanding its footprint across China where R&D and innovation spending is on the rise.
Paul Fong
SINGAPORE AND MALAYSIA COUNTRY MANAGER, DOW CHEMICAL
“Rather than seeing the market adoption of sustainable products as a challenge, I view it as a process of educating the entire value chain; a matter of technological proliferation […]”
Mickey Kertesz
FOUNDER & CEO, KARIUS
The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient’s bloodstream.
Gilles Duqueine & Stéphanie Burgun
PRESIDENT AND CEO & DIRECTOR GENERAL, DUQUEINE RHÔNE-ALPES
The Duqueine Group specializes in the development and production of composite parts for the aerospace industry.
Matthias Vorbeck
GENERAL MANAGER, ANASTACIO OVERSEAS
Anastacio Overseas trades in chemicals sourcing from around the world to supply the Latin American market.
William Hait
GLOBAL HEAD, JOHNSON & JOHNSON GLOBAL EXTERNAL INNOVATION
Johnson & Johnson invested US$10 billion in research and development in 2017 both internally and externally.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
